United Therapeutics (UTHR) Given News Sentiment Rating of 0.17

Press coverage about United Therapeutics (NASDAQ:UTHR) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9647920058204 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

A number of brokerages have recently weighed in on UTHR. Credit Suisse Group raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $115.00 price objective on the stock in a report on Tuesday. BidaskClub upgraded shares of United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 24th. ValuEngine downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 27th. Barclays restated an “underweight” rating and set a $105.00 target price (down from $115.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price for the company in a research report on Monday, January 15th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $135.20.

Shares of United Therapeutics stock traded down $2.77 during trading hours on Friday, reaching $110.26. The stock had a trading volume of 345,297 shares, compared to its average volume of 449,295. The company has a market cap of $5,030.51, a P/E ratio of 10.12 and a beta of 1.34. United Therapeutics has a twelve month low of $106.30 and a twelve month high of $152.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.01 and a current ratio of 3.26.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share for the quarter, topping analysts’ consensus estimates of $3.59 by $0.30. The business had revenue of $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The company’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.12 earnings per share. equities research analysts forecast that United Therapeutics will post 12.46 EPS for the current year.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the transaction, the chief executive officer now owns 21,652 shares in the company, valued at $2,405,753.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 43,024 shares of the company’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $111.14, for a total transaction of $4,781,687.36. Following the completion of the transaction, the chief executive officer now owns 21,652 shares of the company’s stock, valued at approximately $2,406,403.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,533 shares of company stock valued at $17,120,890. Insiders own 7.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/04/06/united-therapeutics-uthr-given-daily-media-sentiment-score-of-0-17/2037588.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.